Rewired.GG Makes Europe’s Largest Ever esports Team Investment
Rewired.GG, the €50m esports venture fund that invests in the global growth of esports, is delighted to announce that it has invested a further €14 million into Team Vitality, taking its total investment to date to €34 million. Today also marks the opening of the new multi-million euro Team Vitality headquarters in Paris, called V.Hive, which will be open to the public. In a world’s first for an esports team, the 10,700 sq ft V.Hive has more than 530 sq ft of store front in the bustling heart of Paris, and will offer engaging esports discoveries and experiences to anyone who walks in.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191106005183/en/
Team Vitality Counter Strike players (from left to right): Alex 'ALEX' McMeekin, Cédric 'RpK' Guipouy, Mathieu 'ZywOo' Herbaut, Dan 'apEX' Madesclaire. (Photo: Business Wire)
Team Vitality is one of the biggest esports teams in Europe and boasts some of the world’s top esports players and coaches. It is one of only ten European esports teams in the League of Legends European Championship franchise; and has recently won the 2019 World Championship for Rocket League, won the 7th season of the prestigious ECS tournament for Counter-Strike:Global Offensive and took 3rd place in the 2019 FIFA World Championship. It is also one of only a few esports teams with blue chip sponsors such as Orange, Renault, Red Bull and adidas.
Rewired.GG forecasts that esports will rival traditional sports such as soccer and basketball and will be a major investment category for institutional investors, funds and investment managers. By 2020 it is estimated that the monthly global esports audience size will be nearly 600 million*, equivalent to the current global audience of the English Premier League.
Today’s investment, along with the €20 million that Team Vitality received from Rewired.GG in November 2018, is thought to be the largest investment into a European esports team to date. The Team, which was founded in 2013 with €10,000, aims to be one of the world’s first $1 billion esports teams.
The funds will be used to support the continued growth of Team Vitality as the team pursues further expansion across India and China, where it is acquiring new players and launching a network of esports academies. Funds will also be used to acquire new players and to launch new lines of merchandise globally: as well as opening V.Hive, the team has also today launched its first Team Vitality brand of limited-edition adidas trainers.
As with any major sport, the business of esports is based on media rights, advertising, prize money, merchandise, sponsorship and partnerships. Revenue from these are growing exponentially.
In 2017 it was estimated that esports generated $655 million in annual revenue, including 38% from sponsorships and 14% from media rights. By 2022, it is forecast that media rights will reach 40% of total esports revenue and that total global esports monetization will reach $3bn.*
CEO of Team Vitality, Nicolas Maurer said:
“In 2013 we started Team Vitality with €10,000. Today Team Vitality has built amazing teams that regularly win tournaments all over the world, and a strong brand that is backed by our amazing and dedicated fans and our premium sponsors. Receiving further backing by Rewired.GG after the initial investment of €20M in November 2018 is a testament to the strength not only of the team but also a comment on the growth of the sector as a whole. This investment will go towards continuing to turn Team Vitality into a global esports brand and we look forward to providing further updates on our future wins as we continue to pursue V for Victory.”
Amit Jain, Principal at Rewired.GG commented:
“Any industry with an audience that’s growing rapidly into hundreds of millions is hugely exciting and esports is no exception. We’ve seen the current esports trend many times before in the tech sector: first the number of eyeballs grows exponentially, and then full monetization comes later. We believe that esports is one of the world’s fastest growing industries today, and the success of teams like Team Vitality show that there is real opportunity for growth in this market. We are well on the way to building one of the world’s first billion-dollar esports teams.”
-ends-
Footnotes and References
*BBC
Video of esports world champion, Rocket League player Kyle ‘Scrub Killa’ Robertson, and esports super-coach Mike ‘Gregan’ Ellis, are available to embed into stories relating to this release, using these links:
Gregan: https://youtu.be/uLN4S1LFVgI
Scrub Killa: https://youtu.be/LSg-rwTeBHk
Images are available to download here and must be attributed to: Team Vitality: https://drive.google.com/drive/folders/1Ol4_J_pdo8S7c6W-YZ8tkgTrfOFPd4Xd
About Rewired.GG
Rewired.GG is an esports venture fund investing in the talent and ideas that are driving the global growth of esports. In November Rewired.GG 2018 backed European esports leader Team Vitality with €20m of investment to create a global esports brand. The investment thesis of the Rewired.GG esports venture fund is that esports is at an exciting tipping point. The NFL earns around $50 per fan, but that number for esports is only $3.20*. Rewired.GG predicts that this upside potential revenue growth per fan combined with rapidly growing global audiences with rapidly-growing spending power, will generate significant future returns.
About Team Vitality
Team Vitality is an international esports organisation that was founded by Nicolas Maurer and Fabien Devide in 2013. The team has players from ten different nationalities and boasts some of the biggest players in the world, including the world No.1 Fifa player, world No.1 CS:GO player, and the world champion Rocket League squad. Team Vitality players compete in a portfolio of 9 games with 10 competitive teams. Team Vitality's main League of Legends roster competes in the League of Legends European Championship (LEC), which they joined after purchasing Gambit Gaming's spot. They are sponsored by Orange, Red Bull, Renault and Adidas.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191106005183/en/
Contact information
To request interviews please use the contact details below:
Helen Tarbet / Simon Compton / Kim van Beeck / Hannah Ratcliff (Buchanan Communications)
rewired@buchanan.uk.com
+44 207 466 5000
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom